John Bencich
2018
In 2018, John Bencich earned a total compensation of $694.7K as Executive Vice President and Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 39% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $163,810 |
|---|---|
| Option Awards | $155,404 |
| Salary | $375,500 |
| Total | $694,714 |
Bencich received $375.5K in salary, accounting for 54% of the total pay in 2018.
Bencich also received $163.8K in non-equity incentive plan and $155.4K in option awards.
Rankings
In 2018, John Bencich's compensation ranked 10,735th out of 14,244 executives tracked by ExecPay. In other words, Bencich earned more than 24.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,735 out of 14,244 | 25th |
Division Manufacturing | 4,322 out of 5,762 | 25th |
Major group Chemicals And Allied Products | 1,631 out of 2,125 | 23rd |
Industry group Drugs | 1,380 out of 1,814 | 24th |
Industry In Vitro and In Vivo Diagnostic Substances | 50 out of 72 | 31st |
Source: SEC filing on March 28, 2019.
Bencich's colleagues
We found three more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2018.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019